Cover Image
市場調查報告書

類風濕性關節炎的亞太地區市場:抗TNF暢銷藥物的專利到期,與新的L-6·JAK抑制劑推動緩和療法

Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2021 - Novel IL-6 and JAK Inhibitors to Stimulate Moderate Growth Despite Brand Erosion of Blockbuster Anti-TNFs

出版商 GBI Research 商品編碼 331413
出版日期 內容資訊 英文 126 Pages
訂單完成後即時交付
價格
Back to Top
類風濕性關節炎的亞太地區市場:抗TNF暢銷藥物的專利到期,與新的L-6·JAK抑制劑推動緩和療法 Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2021 - Novel IL-6 and JAK Inhibitors to Stimulate Moderate Growth Despite Brand Erosion of Blockbuster Anti-TNFs
出版日期: 2015年05月01日 內容資訊: 英文 126 Pages
簡介

亞太地區的類風濕性關節炎 (RA) 治療藥市場,2014年達到56億美元,推算2021年達到69億美元的規模,2014∼2021年的年複合成長率(CAGR) 為3.3%。

本報告提供亞太地區類風濕性關節炎的治療藥市場相關分析、疾病概要和到目前為止的臨床實驗的進展、主要的已上市產品的特徵、現在臨床實驗中的開發中產品的概要、亞太地區市場趨勢預測 (今後8年份關於) 等的調查評估。

第1章 目錄

第2章 簡介

  • 疾病概要
  • 症狀
  • 流行病學
  • 病理處理
  • 診斷法
  • 病因
  • 並存症、併發症
  • 疾病的進展階段
  • 藥物治療的研究
  • 治療選擇
  • 生技藥品之外的治療藥
  • 生物來源、疾病緩和型的抗風濕藥
  • 治療效果測量用的疾病評估手法

第3章 已上市產品

  • 概要
  • 小分子、疾病緩和型的抗風濕藥
    • Methotrexate來源的產品
    • Xeljanz (tofacitinib):Pfizer
  • 生物來源、疾病緩和型的抗風濕藥
    • Remicade (Infliximab):Johnson & Johnson,Merck
    • Humira (Adalimumab):AbbVie
    • Enbrel (etanercept):Amgen,Pfizer,武田藥品工業
    • Rituxan (Rituximab):Genentech,Biogen IDEC
    • Orencia (abataseputo):Bristol-Myers Squibb
    • Simponi (gorimumabu):Johnson & Johnson,Merck
    • Cimzia (serutorizumabupegoru):UCB
    • Kineret (anakinra):Swedish Orphan Biovitrum
    • Actemra (toshirizumabu):Roche
    • 安全性、功效比較
  • 未滿足需求

第4章 產品平台

  • 概要
  • 開發中產品的分佈:各臨床實驗階段、各分子類型、各給藥途徑、各新穎性
  • 開發中產品的分佈:各作用機制
    • 細胞因子抑製劑
    • B/T細胞
    • 細胞間激梅
  • 臨床實驗分析
    • 整體損耗率
    • 各臨床實驗階段、各分子類型、各標的損耗率
    • 平均臨床實驗規模:各分子類型
    • 平均臨床實驗規模:分子的各作用機制
    • 平均臨床實驗機關 (每一分子) :各分子類型
    • 平均臨床實驗機關 (每一分子) :分子的各作用機制
    • 一次、次要的試驗指標
    • 摘要
  • 有前途的開發平台治療藥
    • Baricitinib:Eli Lilly
    • Sarilumab:Regeneron Pharmaceuticals/Sanofi
    • Sirukumab:Johnson & Johnson
    • Decernotinib:Vertex Pharmaceuticals
    • Masitinib
    • Denosumab
  • 比較分析用熱圖

第5章 市場預測

  • 亞太地區
    • 治療藥的利用模式
    • 市場規模
  • 印度
    • 治療藥的利用模式
    • 年度治療費用
    • 市場規模
  • 中國
  • 澳洲
  • 日本
  • 類風濕性關節炎治療藥市場促進、阻礙因素

第6章 資本交易

  • 授權合約 (共6件)
  • 共同開發 (共5件)

第7章 附錄

圖表一覽

目錄
Product Code: GBIHC358MR

Executive Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2021 - Novel IL-6 and JAK Inhibitors to Stimulate Moderate Growth Despite Brand Erosion of Blockbuster Anti-TNFs", which provides in-depth analysis of Rheumatoid Arthritis (RA) market within the Asia-Pacific (APAC) market covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2014, along with market forecast until 2021. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

The value of the RA market in the APAC region amounted to an estimated $5.6 billion in 2014 and is expected to register a Compound Annual Growth Rate (CAGR) of 3.3% to reach $6.9 billion by 2021. The key drivers for growth in the APAC market include: the increasing prevalent population and the anticipated market launch of promising pipeline candidates. The late-stage pipeline which has a potential to stimulate growth during the forecast period include interleukin (IL)-6 inhibitors Sanofi/Regeneron's sarilumab, Johnson & Johnson/GlaxoSmithKline's [J&J/GSK's] sirukumab, small molecules (four janus kinase [JAK] inhibitors: Eli Lilly/Incyte's baricitinib, Loss of patent exclusitivity of major second-line biologic anti-TNF during such as Enbrel, Remicade and Humira by the end of the forecast period is the major barrier for growth in the RA market size in the APAC markets. Preference for less expensive alternatives to branded medicines, such as biosimilars and other alternate therapies is another major barrier in cost-conscious APAC markets, India and China.

Scope

The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts for RA. It covers and includes -

  • A brief introduction to RA, including the disease's pathophysiology, risk factors, diagnosis and an overview of pharmacotherapy and treatment algorithms.
  • In-depth analysis of the drug combinations used in the treatment of RA, including analyses of their safety, efficacy, and place in the disease treatment algorithm, as well as a heat map comparing the drug combinations in terms of safety and efficacy
  • A comprehensive review of the pipeline for OC therapies, including individual analysis of a number of late-stage pipeline drugs that have the potential to enter the market in the forecast period; the pipeline is analyzed on the basis of phase distribution, molecule type and molecular target, and route of administration
  • Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, and trial duration, and program failure rate analyses for each molecule type and mechanism of action
  • Multi-scenario forecast market data to 2021, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and the changes in disease epidemiology across the APAC markets
  • Discussion of the drivers and barriers for market growth
  • In-depth analysis of licensing and co-development deals involving drugs indicated in RA, including an outline of the key deals

Reasons to buy

Primarily, the report will allow clients to gain a strong understanding of RA, helping to identify and clarify market opportunities and the competitive environment. It will also allow you to -

  • Understand the RA pipeline and the key trends in the current product development landscape
  • Observe detailed profiles for the promising pipeline products, including revenue forecasts, and gain an insight into how they are likely to compete in the market, and what their main competitors will be
  • Follow the trends in RA clinical trial size and duration in relation to industry averages and assess the potential risk of future developmental programs for RA therapeutics, depending on the mechanism of action, by considering the recorded clinical trial failure rates
  • Observe the potential growth patterns expected for the RA market over the forecast period, and identify which countries are expected to make the biggest contribution to this growth.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Introduction
  • 2.2. Symptoms
  • 2.3. Etiology
  • 2.4. Pathophysiology
  • 2.5. Diagnosis
    • 2.5.1. Physical Examination
    • 2.5.2. Blood Tests
    • 2.5.3. 1987 Rheumatoid Arthritis Classification
    • 2.5.4. 2010 ACR-EULAR Classification Criteria for Rheumatoid Arthritis
  • 2.6. Epidemiology
  • 2.7. Co-morbidities and Complications
  • 2.8. Disease Progression
  • 2.9. Pharmacotherapy Algorithm
  • 2.10. Treatment Options
    • 2.10.1. Pharmacological
    • 2.10.2. Methotrexate
    • 2.10.3. Hydroxychloroquine
    • 2.10.4. Leflunomide
    • 2.10.5. Sulfasalazine
    • 2.10.6. Cyclosporine
    • 2.10.7. Prograf (tacrolimus)
    • 2.10.8. Xeljanz (tofacitinib)
  • 2.11. Other Non-biologics
    • 2.11.1. Non-steroidal Anti-inflammatory Drugs
    • 2.11.2. Painkillers
    • 2.11.3. Glucocorticoids
  • 2.12. Biologic Disease-Modifying Anti-rheumatic Drugs
    • 2.12.1. Tumor Necrosis Factor Alpha Inhibitors
    • 2.12.2. Interleukin Inhibitors
    • 2.12.3. Other Biologics that Target B- and T-Cell Antigens
  • 2.13. Disease Scoring Methods for Measuring Treatment Efficacy
    • 2.13.1. Radiographic Progression
    • 2.13.2. Clinical Disease Activity Index and Simplified Disease Activity Index
    • 2.13.3. Disease Activity Score-28
    • 2.13.4. American College of Rheumatology
    • 2.13.5. Health Assessment Questionnaire

3. Marketed Products

  • 3.1. Overview
  • 3.2. Small-Molecule Disease-Modifying Anti-rheumatic Drugs
    • 3.2.1. Methotrexate-Based Products
    • 3.2.2. Xeljanz (tofacitinib) - Pfizer
  • 3.3. Biologic Disease-Modifying Anti-rheumatic Drugs
    • 3.3.1. Remicade (infliximab) - Johnson & Johnson, Merck
    • 3.3.2. Humira (adalimumab) - AbbVie
    • 3.3.3. Enbrel (etanercept) - Amgen, Pfizer and Takeda Pharmaceutical
    • 3.3.4. Rituxan (rituximab) - Genentech, Biogen IDEC
    • 3.3.5. Orencia (abatacept) - Bristol-Myers Squibb
    • 3.3.6. Simponi (golimumab) - Johnson & Johnson, Merck
    • 3.3.7. Cimzia (certolizumab pegol) - UCB
    • 3.3.8. Kineret (anakinra) - Swedish Orphan Biovitrum
    • 3.3.9. Actemra (tocilizumab) - Roche
    • 3.3.10. Comparative Safety and Efficacy
  • 3.4. Unmet Need

4. Product Pipeline

  • 4.1. Overview
  • 4.2. Pipeline Distribution by Phase of Development, Molecule Type, Route of Administration and Novelty
  • 4.3. Pipeline Distribution by Mechanism of Action
    • 4.3.1. Cytokine Inhibitors
    • 4.3.2. B- and T-cells
    • 4.3.3. Intracellular Kinases
  • 4.4. Clinical Trial Analysis
    • 4.4.1. Overall Attrition Rate
    • 4.4.2. Attrition Rate by Phase, Molecule Type and Target
    • 4.4.3. Average Clinical Trial Size by Molecule Type
    • 4.4.4. Average Clinical Trial Size by Mechanism of Action
    • 4.4.5. Average Clinical Trial Duration per Molecule Type by Product
    • 4.4.6. Average Clinical Trial Duration per Mechanism of Action by Product
    • 4.4.7. Primary and Secondary Endpoints
    • 4.4.8. Summary
  • 4.5. Promising Pipeline Drugs
    • 4.5.1. Baricitinib - Eli Lilly
    • 4.5.2. Sarilumab - Regeneron Pharmaceuticals/Sanofi
    • 4.5.3. Sirukumab - Johnson & Johnson
    • 4.5.4. Decernotinib - Vertex Pharmaceuticals
    • 4.5.5. Masitinib
    • 4.5.6. Denosumab
  • 4.6. Comparative Heat Map

5. Market Forecasts

  • 5.1. Asia-Pacific
    • 5.1.1. Treatment Usage Patterns
    • 5.1.2. Market Size
  • 5.2. India
    • 5.2.1. Treatment Usage Patterns
    • 5.2.2. Annual Cost of Therapy
    • 5.2.3. Market Size
  • 5.3. China
    • 5.3.1. Treatment Usage Patterns
    • 5.3.2. Annual Cost of Therapy
    • 5.3.3. Market Size
  • 5.4. Australia
    • 5.4.1. Treatment Usage Patterns
    • 5.4.2. Annual Cost of Therapy
    • 5.4.3. Market Size
  • 5.5. Japan
    • 5.5.1. Treatment Usage Patterns
    • 5.5.2. Annual Cost of Therapy
    • 5.5.3. Market Size
  • 5.6. Drivers and Barriers of Rheumatoid Arthritis Therapeutics Market
    • 5.6.1. Drivers
    • 5.6.2. Barriers

6. Deals

  • 6.1. Licensing Agreements
    • 6.1.1. Deal Values by Therapeutic Molecule Type
    • 6.1.2. Deal Values by Therapeutic Mechanism of Action
    • 6.1.3. AstraZeneca Enters into Licensing Agreement with Rigel Pharma for Fostamatinib Disodium
    • 6.1.4. Alder Biopharmaceuticals Enters into Licensing Deal with Bristol-Myers Squibb and Alder Biopharmaceuticals for Clazakizumab
    • 6.1.5. Janssen Biotech Enters into a Licensing Deal with Astellas Pharma for Peficitinib
    • 6.1.6. Ablynx Enters into a Licensing Deal with AbbVie for the Nanobody ALX-006
  • 6.2. Co-development
    • 6.2.1. Deal Values by Therapeutic Molecule Type and Phase
    • 6.2.2. Deal Values by Therapeutic Mechanism of Action and Phase
    • 6.2.3. GlaxoSmithKline enters into Global Agreement with Archemix
    • 6.2.4. Abbott Laboratories Enters into Global Collaboration with Galapagos for filgotinib
    • 6.2.5. Chroma Therapeutics Enters into a Co-development Agreement with GlaxoSmithKline

7. Appendix

  • 7.1. All Pipeline Drugs by Phase of Development
    • 7.1.1. Discovery
    • 7.1.2. Preclinical
    • 7.1.3. IND-CTA Filed
    • 7.1.4. Phase I
    • 7.1.5. Phase II
    • 7.1.6. Phase III
  • 7.2. Market Forecasts to 2021
  • 7.3. Abbreviations
  • 7.4. Bibliography
    • 7.4.1. References for Figure 10
    • 7.4.2. References for Figure 26
  • 7.5. Research Methodology
    • 7.5.1. Coverage
    • 7.5.2. Secondary Research
    • 7.5.3. Primary Research
    • 7.5.4. Therapeutic Landscape
    • 7.5.5. Geographical Landscape
    • 7.5.6. Pipeline Analysis
  • 7.6. Expert Panel Validation
  • 7.7. Contact Us
  • 7.8. Disclaimer

List of Tables

  • Table 1: ACR-EULAR Classification Criteria for Rheumatoid Arthritis, 2010
  • Table 2: Rheumatoid Arthritis, Therapeutics, Global, All Pipeline Products, Discovery, 2014
  • Table 3: Rheumatoid Arthritis, Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2014
  • Table 4: Rheumatoid Arthritis, Therapeutics, Global, All Pipeline Products, IND/CTA-Filed, 2014
  • Table 5: Rheumatoid Arthritis, Therapeutics, Global, All Pipeline Products, Phase I, 2014
  • Table 6: Rheumatoid Arthritis, Therapeutics, Global, All Pipeline Products, Phase II, 2014
  • Table 7: Rheumatoid Arthritis, Therapeutics, Global, All Pipeline Products, Phase III, 2014
  • Table 8: Rheumatoid Arthritis, Therapeutics Market, Asia-Pacific, Market Forecast, 2014-2021
  • Table 9: Rheumatoid Arthritis, Therapeutics Market, India, Market Forecast, 2014-2021
  • Table 10: Rheumatoid Arthritis, Therapeutics Market, China, Market Forecast, 2014-2021
  • Table 11: Rheumatoid Arthritis, Therapeutics Market, Australia, Market Forecast, 2014-2021
  • Table 12: Rheumatoid Arthritis, Therapeutics Market, Japan, Market Forecast, 2014-2021
  • Table 13: Abbreviations

List of Figures

  • Figure 1: American College of Rheumatology Treatment Guidelines, 2012
  • Figure 2: Rheumatoid Arthritis Market, Global, Annual Sales of Remicade ($bn), 2008-2014
  • Figure 3: Rheumatoid Arthritis Market, Global, Annual Sales of Humira ($bn), 2008-2014
  • Figure 4: Rheumatoid Arthritis Market, Global, Annual Sales of Enbrel ($bn), 2008-2014
  • Figure 5: Rheumatoid Arthritis Market, Global, Annual Sales of Rituxan ($bn), 2008-2014
  • Figure 6: Rheumatoid Arthritis Market, Global, Annual Sales of Orencia ($m), 2008-2014
  • Figure 7: Rheumatoid Arthritis Market, Global, Annual Sales of Simponi ($m), 2009-2014
  • Figure 8: Rheumatoid Arthritis Market, Global, Annual Sales of Cimzia ($m), 2008-2014
  • Figure 9: Rheumatoid Arthritis Market, Global, Annual Sales of Actemra ($m), 2008-2014
  • Figure 10: Comparative Efficacy and Safety of Marketed Products
  • Figure 11: Rheumatoid Arthritis Market, Global, Pipeline, 2014
  • Figure 12: Rheumatoid Arthritis Market, Global, Pipeline by Mechanism of Action, 2014
  • Figure 13: Rheumatoid Arthritis Market, Global, Pipeline, Cytokine Inhibitors, 2014
  • Figure 14: Rheumatoid Arthritis Market, Global, Pipeline, Inhibitors of B and T Cells, 2014
  • Figure 15: Rheumatoid Arthritis Market, Global, Pipeline, Intracellular Kinase Inhibitors, 2014
  • Figure 16: Rheumatoid Arthritis, Global, Clinical Trial Failure Rate (%), 2006-2014
  • Figure 17: Rheumatoid Arthritis, Global, Clinical Trial Failure Rate (%), 2006-2014
  • Figure 18: Rheumatoid Arthritis, Global, Clinical Trial Failure Rate (%), 2006-2014
  • Figure 19: Rheumatoid Arthritis Market, Global, Pipeline, Clinical Trial Size by Molecule Type by Product, 2006-2014
  • Figure 20: Rheumatoid Arthritis Market, Global, Pipeline, Clinical Trial Size by Molecule Type by Trial, 2006-2014
  • Figure 21: Rheumatoid Arthritis Market, Global, Pipeline, Clinical Trial Size by Mechanism of Action by Product, 2006-2014
  • Figure 22: Rheumatoid Arthritis Market, Global, Pipeline, Clinical Trial Size by Mechanism of Action by Trial, 2006-2014
  • Figure 23: Rheumatoid Arthritis Market, Global, Pipeline, Clinical Trial Duration by Molecule Type by Product (months), 2006-2014
  • Figure 24: Rheumatoid Arthritis Market, Global, Pipeline, Clinical Trial Duration by Mechanism of Action by Product (months), 2006-2014
  • Figure 25: Rheumatoid Arthritis Market, Global, Frequency of Primary Endpoints Measured in Clinical Trials, 2006-2014
  • Figure 26: Comparative Efficacy and Safety of Pipeline Programs
  • Figure 27: Rheumatoid Market, Asia-Pacific, Treatment Usage Patterns (million), 2014-2021
  • Figure 28: Rheumatoid Market, Asia-Pacific, Market Size ($bn), 2014-2021
  • Figure 29: Rheumatoid Market, India, Treatment Usage Patterns (million), 2014-2021
  • Figure 30: Rheumatoid Market, India, Annual Cost of Therapy ($), 2014-2021
  • Figure 31: Rheumatoid Market, India, Market Size ($m), 2014-2021
  • Figure 32: Rheumatoid Market, China, Treatment Usage Patterns (million), 2014-2021
  • Figure 33: Rheumatoid Market, China, Annual Cost of Therapy ($), 2014-2021
  • Figure 34: Rheumatoid Market, China, Market Size ($m), 2014-2021
  • Figure 35: Rheumatoid Market, Australia, Treatment Usage Patterns ('000), 2014-2021
  • Figure 36: Rheumatoid Market, Australia, Annual Cost of Therapy ($), 2014-2021
  • Figure 37: Rheumatoid Market, Australia, Market Size ($m), 2014-2021
  • Figure 38: Rheumatoid Market, Japan, Treatment Usage Patterns ('000), 2014-2021
  • Figure 39: Rheumatoid Market, Japan, Annual Cost of Therapy ($), 2014-2021
  • Figure 40: Rheumatoid Market, Japan, Market Size ($bn), 2014-2021
  • Figure 41: Rheumatoid Arthritis Market, Global, Licensing Deals, 2006-2014
  • Figure 42: Rheumatoid Arthritis Market, Global, Licensing Deals, 2006-2014
  • Figure 43: Rheumatoid Arthritis Market, Global, Licensing Deals, 2006-2014
  • Figure 44: Rheumatoid Arthritis Market, Global, Co-development Deals, 2006-2014
  • Figure 45: Rheumatoid Arthritis Market, Global, Co-development Deals, 2006-2014
  • Figure 46: Rheumatoid Arthritis Market, Global, Co-development Deals, 2006-2014
  • Figure 47: GBI Research Market Forecasting Model
Back to Top